Home Factor company Global Melanoma Treatment Industry to 2027 – Players include Novartis, Pfizer, Sanofi and AstraZeneca – ResearchAndMarkets.com

Global Melanoma Treatment Industry to 2027 – Players include Novartis, Pfizer, Sanofi and AstraZeneca – ResearchAndMarkets.com


DUBLIN–(BUSINESS WIRE)–Report “Melanoma Treatment Market – Forecast 2022 to 2027” has been added to from ResearchAndMarkets.com offer.

In recent years, there has been an increase in the number of new cases reported due to climate change. These changes are increasing the incidence of melanoma patients worldwide, increasing the demand for appropriate treatment methods. If detected and treated early, the disease is almost always curable.

Rising per capita income, better healthcare facilities, growing health awareness, availability of health insurance services, and advancements in medical science and biomedicine are also contributing to the expansion of the market.

Geographically, North America dominates the market share. The high prevalence of skin cancers in the United States is a major factor contributing to the growth of the market. By type, cutaneous melanoma is widely spread around the world due to too much exposure to ultraviolet rays from the sun and artificial tanning. Based on therapy, targeted therapy is gaining market share due to lower side effects and high efficacy rates.

Growth factors

Growing regulatory approvals

The high importance and hence high investment in the development of effective treatment options is likely to have a positive impact on the growth of the market. Treatment recommendations depend on many factors, and the increasing number of regulatory approvals has had the greatest impact on the market growth.

In 2021, Aldesleukin, Binimetinib, Braftovi (Encorafenib), Cobimetinib Fumarate, Cotellic (Cobimetinib Fumarate), Dabrafenib Mesylate, etc. were among the drugs approved for treatment by the FDA. The focus of prominent companies on the introduction of innovative treatment options and drugs will help drive the growth of the market in the coming years.

Impact of COVID-19 on the Melanoma Treatment Market

The pandemic has had a delayed effect on various diagnostic methods due to several restrictions and risk exposure of patients with comorbidity. A drastic reduction in skin biopsies was observed early in the COVID-19 pandemic, which disproportionately affected older people, women, and certain geographic regions. Efforts have been made by the government to contain the situation without further delay.

Competitive outlook.

  • In 2021, Oncosec Medical Inc. and Merck and Co. collaborated to study stage III metastatic melanoma.

  • In 2021, Amgen completed the acquisition of Five Prime Therapeutics, a clinical-stage biotechnology company focused on the development of immuno-oncology and targeted cancer therapies, for $38.00 per share and is poised to acquire Teneobio, a private clinical-stage biotechnology company.

  • In 2020, Iovance Biotherapeutics, Inc sold $500 million of its common stock, subject to market and other conditions, in a subscribed public offering. In 2021, there has been some turbulence and the company is looking for buyout options.

  • In 2019, Bristol-Myers Squibb Company and Celgene Corporation entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene for approximately $74 billion to create an innovative biopharmaceutical company.

  • In 2020 Novartis AG acquired The Medicines Company and in 2018 GlaxoSmithKline plc reached an agreement with Novartis to buy Novartis’ 36.5% stake in their Consumer Healthcare joint venture for $13 billion.

  • In 2020, the FDA approved the drug selumetinib from AstraZeneca and Merck & Co. to treat neurofibromatosis type 1, or NF1, a rare and usually inherited condition that causes tumors to grow inside nerve sheaths. Merck joined AstraZeneca to develop and commercialize Koselugo in a deal that included the ovarian cancer drug Lynparza.

Companies cited

  • Merck & Co. Inc.

  • Amgen Inc.

  • Iovance Biotherapeutics, Inc,

  • Bristol Myers Squibb

  • F. Hoffmann-La Roche SA

  • Eisai Co., Ltd.

  • Novartis AG

  • Pfizer Inc.

  • Sanofi

  • Astra Zeneca

Market segmentation :

By type

  • Cutaneous melanoma

  • Ocular melanoma

  • mucosal melanoma

By therapy

  • Operation

  • Immunotherapy

  • Targeted therapy

  • Chemotherapy

  • Radiotherapy

By geography

  • North America


  • Canada

  • Mexico

  • South America

  • Brazil

  • Argentina

  • Others

  • Europe

  • UK

  • Germany

  • France

  • Spain

  • Others

  • Middle East and Africa

  • Saudi Arabia

  • Israel

  • Others

  • Asia Pacific

  • Japan

  • China

  • India

  • Indonesia

  • Taiwan

  • Thailand

  • Others

For more information on this report, visit https://www.researchandmarkets.com/r/i7arc8